Suleman specialises in the genomics and immunology areas. He has handled patent cases involving novel genes, T cell and genetic diagnostics, engineered enzymes, crystal structures, antibodies, immuno-tolerisation, vaccines and screening assays.
Suleman has drafted patent applications for small and medium sized biotech companies, large pharmaceutical companies and technology transfer offices. He has prosecuted biotech cases in many different territories and has built up knowledge of biotech case law around the world, and in particular has developed examination strategies for US patent cases. Suleman has extensive experience in both attacking and defending cases in oppositions at the EPO. He has also handled many appeal cases at the EPO and has experience of how strategy needs to be different from first instance proceedings.
Suleman was part of the Human Genome Sciences litigation team in the UK proceedings HGS v Eli Lilly. He has worked closely with technology transfer offices and biotech research companies assisting in aligning patent strategy with commercial goals. In particular he has advised on invention harvesting, building patent portfolios, due diligence and working with investors.